ArticleEndocrinology and metabolism (Seoul, Korea)2021
Antithyroid Drug Treatment in Graves' Disease.
Article in Endocrinology and metabolism (Seoul, Korea), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- 2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism.Endocrinology and metabolism (Seoul, Korea) · 2025Guideline
- From Induction to Maintenance? Rethinking GLP-1-Based Obesity Pharmacotherapy in the Era of Oral Agents.Diabetes, obesity & metabolism · 2026Article
- The diagnosis and treatment of hyperthyroidism: a bibliometric analysis from 2004 to 2024.Gland surgery · 2025Article
- Unveiling Risk Factors for Treatment Failure in Patients with Graves' Disease: A Nationwide Cohort Study in Korea.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Dynamic Risk Model for the Medical Treatment of Graves' Hyperthyroidism according to Treatment Duration.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Increased risk of incident gout in patients with hyperthyroidism: a nationwide retrospective cohort study.Rheumatology international · 2024Article
- The influence of thionamides on intra-thyroidal uptake ofScientific reports · 2023Article
- Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed graves' disease.Eye (London, England) · 2023Article
- Methimazole, an Effective Neutralizing Agent of the Sulfur Mustard Derivative 2-Chloroethyl Ethyl Sulfide.ACS bio & med chem Au · 2023Article
- Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.European thyroid journal · 2023Article
- Application of oral inorganic iodine in the treatment of Graves' disease.Frontiers in endocrinology · 2023Review
- Usefulness of Real-Time Quantitative Microvascular Ultrasonography for Differentiation of Graves' Disease from Destructive Thyroiditis in Thyrotoxic Patients.Endocrinology and metabolism (Seoul, Korea) · 2022Observational
- Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study.Endocrinology and metabolism (Seoul, Korea) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' disease is associated with thyrotropin (TSH) receptor stimulating antibody, for which there is no therapeutic agent. This disease is currently treated through inhibition of thyroid hormone synthesis or destruction of the thyroid gland. Recurrence after antithyroid drug (ATD) treatment is common. Recent studies have shown that the longer is the duration of use of ATD, the higher is the remission rate. Considering the relationship between clinical outcomes and iodine intake, recurrence of Graves' disease is more common in iodine-deficient areas than in iodine-sufficient areas. Iodine restriction in an iodine-excessive area does not improve the effectiveness of ATD or increase remission rates. Recently, Danish and Korean nationwide studies noted significantly higher prevalence of birth defects in newborns exposed to ATD during the first trimester compared to that of those who did not have such exposure. The prevalence of birth defects was lowest when propylthiouracil (PTU) was used and decreased by only 0.15% when methimazole was changed to PTU in the first trimester. Therefore, it is best not to use ATD in the first trimester or to change to PTU before pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.